My title
» Cardiovascular

Cardiovascular

 

CARDIOVASCULAR CLINICAL TRIALS

 

STROKE/TIA
Study Link Study Status Study Title Principal Investigator
RESPECT-ESUS Active-Enrolling Randomized, double-blind, evaluation in secondary stroke prevention comparing the efficacy and safety of the oral thrombin inhibitor dabigatran etexilate (110 mg or 150 mg, oral b.i.d.) versus acetylsalicylic acid (100 mg oral

q.d.) in patients with embolic stroke of undetermined source (RESPECT ESUS)

PI: Welker
VENOUS THROMBOEMBOLISM
Study Link Study Status Study Title Principal Investigator
GARFIELD-VTE Active-Enrolling Global Anticoagulant Registry in the FIELD Observing Treatment and Outcomes In Patient With Treated Acute Venous Thromboembolic Events In The Real World PI: Welker
MARINER Active-Enrolling Medically Ill Patient Assessment of Rivaroxaban Versus Placebo IN Reducing Post-Discharge Venous Thrombo-Embolism Risk PI: Welker
CONGESTIVE HEART FAILURE
Study Link Study Status Study Title Principal Investigator
RELAX Active A multicenter, randomized, double-blind, placebo controlled phase IIIb study to evaluate the efficacy, safety

and tolerability of Serelaxin when added to standard therapy in acute heart failure patients

PI: Welker
HYPERLIPIDEMIA
Study Link Study Status Study Title Principal Investigator
FOURIER Active A Double-blind, Randomized, Placebo-controlled, Multicenter Study Assessing the Impact of Additional LDL-Cholesterol Reduction on Major Cardiovascular Events When Evolocumab (AMG 145) is Used in Combination With Statin Therapy in Patients with Clinically Evident Cardiovascular Disease PI: Welker
ODYSSEY Active A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Effect of Alirocumab (SAR236553/REGN727) on the Occurrence of Cardiovascular Events in Patients Who Have Recently Experienced an Acute Coronary Syndrome PI: Welker
SPIRE 1 Active  

B1481022-PHASE 3 MULTI-CENTER, DOUBLE-BLIND, RANDOMIZED, PLACEBO-CONTROLLED, PARALLEL GROUP EVALUATION OF THE EFFICACY, SAFETY, AND TOLERABILITY OF BOCOCIZUMAB (PF-04950615), IN REDUCING THE OCCURRENCE OF MAJOR CARDIOVASCULAR EVENTS IN HIGH RISK SUBJECTS

PI: Welker
SPIRE 2 Active B1481038-PHASE 3 MULTI-CENTER, DOUBLE-BLIND, RANDOMIZED, PLACEBO-CONTROLLED, PARALLEL GROUP EVALUATION OF THE EFFICACY, SAFETY, AND TOLERABILITY OF BOCOCIZUMAB (PF-04950615), IN REDUCING THE OCCURRENCE OF MAJOR CARDIOVASCULAR EVENTS IN HIGH RISK SUBJECTS

 

PI: Welker
MYOCARDIAL INFARCTION
Study Link Study Status Study Title Principal Investigator
ARTEMIS Active Affordability and Real-world Antiplatelet Treatment Effectiveness After Myocardial Infarction Study PI: Welker
Dal-GenE Active-Enrolling A phase III, double-blind, randomized placebo-controlled study to evaluate the effects of dalcetrapib on cardiovascular (CV) risk in a genetically defined population with a recent Acute Coronary Syndrome (ACS) PI: Welker
ATRIAL FIBRILLATION
Study Link Study Status Study Title Principal Investigator
Garfield

TRI08888

Active  

Prospective, multicentre, international Registry of male and female patients newly diagnosed with atrial fibrillation.
PI: Welker

 

Our Studies